Julie Beaulac1, Kim Corace1,2, Louise Balfour1,2, Mark Kaluzienski2, Curtis Cooper1,2,3. 1. Ottawa Hospital Research Institute, Ottawa, Ontario. 2. Faculty of Medicine, University of Ottawa, Ottawa, Ontario. 3. Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, Ontario.
Abstract
Background: Although hepatitis C virus (HCV) treatment has improved dramatically, decision making related to treatment continues to be complex and challenging. Little data exists regarding patient information needs and preferences in the direct-acting antiviral (DAA) era. Methods: We evaluated patient-perceived information needs and preferences when making HCV treatment decisions. A cross-sectional survey was conducted at two Ottawa-based sites: a hospital-located outpatient viral hepatitis clinic, and a community-based HCV patient support program. Results: One hundred and seventeen patients completed the survey: the mean age was 52.1 years (range 23 to 78), and 64% were male, 81.5% were White, 48.6% were on disability support or leave, and 60.3% had a high school education or less. Although traditional sources of health information (e.g., direct communication with health care providers) remain preferred by most, a range of preferences were reported including utilization of newer technologies (e.g., emails, text messages). The telephone was rated as the preferred method of contact for medication reminders, with daily or weekly communication reported as most helpful. White participants, those more highly educated, and those with a higher income all indicated a greater acceptability for e-mail and/or text message communication for medication and appointment reminders. Conclusions: There is no single preferred source or method of communicating with patients. These findings indicate that a tailored multi-pronged approach, including newer technologies, is more likely to effectively educate and communicate with the heterogeneous population of individuals living with HCV.
Background: Although hepatitis C virus (HCV) treatment has improved dramatically, decision making related to treatment continues to be complex and challenging. Little data exists regarding patient information needs and preferences in the direct-acting antiviral (DAA) era. Methods: We evaluated patient-perceived information needs and preferences when making HCV treatment decisions. A cross-sectional survey was conducted at two Ottawa-based sites: a hospital-located outpatient viral hepatitis clinic, and a community-based HCV patient support program. Results: One hundred and seventeen patients completed the survey: the mean age was 52.1 years (range 23 to 78), and 64% were male, 81.5% were White, 48.6% were on disability support or leave, and 60.3% had a high school education or less. Although traditional sources of health information (e.g., direct communication with health care providers) remain preferred by most, a range of preferences were reported including utilization of newer technologies (e.g., emails, text messages). The telephone was rated as the preferred method of contact for medication reminders, with daily or weekly communication reported as most helpful. White participants, those more highly educated, and those with a higher income all indicated a greater acceptability for e-mail and/or text message communication for medication and appointment reminders. Conclusions: There is no single preferred source or method of communicating with patients. These findings indicate that a tailored multi-pronged approach, including newer technologies, is more likely to effectively educate and communicate with the heterogeneous population of individuals living with HCV.
Authors: Russell E Glasgow; Edward H Wagner; Judith Schaefer; Lisa D Mahoney; Robert J Reid; Sarah M Greene Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: Kylie I Bernstein; Stephen Promislow; Rachel Carr; Patricia Rawsthorne; John R Walker; Charles N Bernstein Journal: Inflamm Bowel Dis Date: 2011-02 Impact factor: 5.325
Authors: Dawn Stacey; France Légaré; Nananda F Col; Carol L Bennett; Michael J Barry; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; Richard Thomson; Lyndal Trevena; Julie H C Wu Journal: Cochrane Database Syst Rev Date: 2014-01-28
Authors: Julie E Volkman; Tana M Luger; Kimberly L L Harvey; Timothy P Hogan; Stephanie L Shimada; Daniel Amante; D Keith McInnes; Hua Feng; Thomas K Houston Journal: BMC Fam Pract Date: 2014-06-06 Impact factor: 2.497